Improved survival of locoregional-advanced larynx and hypopharynx cancer patients treated according to the DeLOS-II protocol
Gunnar Wichmann(Leipzig University of Applied Sciences), Andreas Dietz(Klinik und Poliklinik für Hals-, Nasen-, Ohrenheilkunde), Peter Hambsch(Leipzig University), Matthaeus Stoehr(University Hospital Leipzig), Regine Kluge(Klinik und Poliklinik für Nuklearmedizin), Florian Lordick(Leipzig University), Markus Pirlich(University Hospital Leipzig), Theresa Wald(University Hospital Leipzig), Irene Krücken(University Hospital Leipzig), Thomas Kuhnt(Leipzig University), Veit Zebralla(University Hospital Leipzig), Nils H. Nicolay(University Hospital Leipzig), Karl‐Titus Hoffmann(Leipzig University), Susanna Wiegand(Charité - Universitätsmedizin Berlin)
Cited by 6
Related Papers
Gastric cancer
|The Lancet|2020|4.8k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2022|1.4k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k